Nuclear BCL10 translocation contributes to lymphoma progression and poor prognosis of peripheral T-cell lymphomas.

Authors

Wei-Li Ma, Ming-Feng Wei, Chia-Lang Hsu, Ming Yao, Hsiao-Wei Lee, Shang-Ju Wu, Chung-Wu Lin, Chang-Tsu Yuan, Chin-Hao Chang, Ann-Lii Cheng, Sung-Hsin Kuo

Published in

European journal of pharmacology. Pages 179479. Oct 26, 2026. Epub Oct 26, 2026.

Abstract

We evaluated the clinical and biological significance of nuclear BCL10 localization and related signaling in peripheral T-cell lymphomas (PTCLs).
We examined the expression of signaling molecules linked to apoptosis, and AKT/BCL10/BCL3/NF-κB-related signaling molecules in both T-cell lymphoma (TCL) cell lines (SR786 and HuT78). Two TCL cells treated with or without siBCL10 transfection were injected into the mice's flanks in order to evaluate the anti-tumor efficacy of BCL10 knockdown in the xenograft model. We assessed the expression patterns of phosphorylated (p)-AKT/BCL10/BCL3/NF-κB (p65) in tumor cells in 95 patients with PTCLs using immunohistochemical staining.
In both TCL cell lines, siBCL10 inhibited cell viability, arrested cell cycles in the sub-G1 phase, and enhanced the cytotoxicity of doxorubicin and gemcitabine. The siBCL10 upregulated the expression of cleaved PARP, downregulated the expression of nuclear BCL3, NF-κB, and MYC, and reduced the transcriptional activity of NF-κB and NF-κB signaling-related molecules in both TCL cell lines. In both TCL cell lines-derived xenograft mouse models, siBCL10 attenuated tumor growth in TCLs. Patients expressing p-AKT (p = 0.025), nuclear BCL10 (p = 0.001), nuclear BCL3 (p = 0.010), or nuclear NF-κB (p = 0.010) had shorter 5-year overall survival (OS) rates than those not expressing them, respectively. Genetic alterations in T-cell receptor-signaling pathways were more often found in patients with nuclear BCL10 expression. Patients with both nuclear BCL10 expression and RHOA mutation had a significantly worse OS than those without either expression or mutation (p = 0.008).
Nuclear BCL10 translocation contributes to lymphoma progression and poor prognosis in PTCLs by activating NF-κB signaling.

PMID:
42933765
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.